A new system has been used to test the influence of levamisole on T- cell function. Evidence has been produced that prior exposure to the drug “protects” normal human peripheral blood lymphocytes from the inhibition that cytotoxic sera from patients with Hodgkin's disease and systemic lupus erythematosus exhibit on their E-rosette-forming capacity. Also, damage of this T-cell function already induced by Hodgkin's sera may be partially corrected.

Topics:
hodgkin's disease, levamisole, serum, systemic lupus erythematosus, lymphocytes, t-lymphocytes
This content is only available as a PDF.
Copyright © 1979 by The American Society of Hematology
1979
Sign in via your Institution